RAYHUNTA Trademark

Trademark Overview


On Thursday, July 25, 2019, a trademark application was filed for RAYHUNTA with the United States Patent and Trademark Office. The USPTO has given the RAYHUNTA trademark a serial number of 79270919. The federal status of this trademark filing is REGISTERED as of Tuesday, December 1, 2020. This trademark is owned by JCR Pharmaceuticals Co., Ltd.. The RAYHUNTA trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the treatment of central nervous system disorders; pharmaceutical preparations for the treatment of peripheral nervous system disorders; pharmaceutical preparations for the treatment of growth deficiencies; pharmaceutical preparations for the treatment of enzyme deficiencies; pharmaceutical preparations for the treatment of lysosomal storage diseases; pharmaceutical preparations for the treatment of Fabry disease, Gaucher disease, GM1 Gangliosidosis, GM2 Gangliosidosis, Krabbe disease, Niemann-Pick disease, Metachromatic leukodystrophy, Hurier syndrome, Hunter disease, Sanfilippo syndrome, Morquio syndrome, Sly syndrome, Pompe disease, Alfa-mannosidosis disease, Fucosidosis disease, and Neuronal ceroid lipofuscinosis
rayhunta

General Information


Serial Number79270919
Word MarkRAYHUNTA
Filing DateThursday, July 25, 2019
Status700 - REGISTERED
Status DateTuesday, December 1, 2020
Registration Number6207918
Registration DateTuesday, December 1, 2020
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, September 15, 2020

Trademark Statements


Goods and ServicesPharmaceutical preparations for the treatment of central nervous system disorders; pharmaceutical preparations for the treatment of peripheral nervous system disorders; pharmaceutical preparations for the treatment of growth deficiencies; pharmaceutical preparations for the treatment of enzyme deficiencies; pharmaceutical preparations for the treatment of lysosomal storage diseases; pharmaceutical preparations for the treatment of Fabry disease, Gaucher disease, GM1 Gangliosidosis, GM2 Gangliosidosis, Krabbe disease, Niemann-Pick disease, Metachromatic leukodystrophy, Hurier syndrome, Hunter disease, Sanfilippo syndrome, Morquio syndrome, Sly syndrome, Pompe disease, Alfa-mannosidosis disease, Fucosidosis disease, and Neuronal ceroid lipofuscinosis

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateFriday, November 8, 2019
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameJCR Pharmaceuticals Co., Ltd.
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressJP

Party NameJCR Pharmaceuticals Co., Ltd.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressJP

Party NameJCR Pharmaceuticals Co., Ltd.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressJP

Trademark Events


Event DateEvent Description
Sunday, March 28, 2021FINAL DECISION TRANSACTION PROCESSED BY IB
Monday, March 8, 2021FINAL DISPOSITION NOTICE SENT TO IB
Monday, March 8, 2021FINAL DISPOSITION PROCESSED
Monday, March 1, 2021FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Tuesday, December 1, 2020REGISTERED-PRINCIPAL REGISTER
Tuesday, September 15, 2020OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, September 15, 2020PUBLISHED FOR OPPOSITION
Wednesday, August 26, 2020NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Monday, August 10, 2020APPROVED FOR PUB - PRINCIPAL REGISTER
Monday, March 16, 2020NOTIFICATION OF NON-FINAL ACTION E-MAILED
Monday, March 16, 2020NON-FINAL ACTION E-MAILED
Monday, March 16, 2020NON-FINAL ACTION WRITTEN
Monday, March 2, 2020TEAS/EMAIL CORRESPONDENCE ENTERED
Monday, March 2, 2020CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, February 25, 2020ASSIGNED TO LIE
Thursday, February 20, 2020TEAS RESPONSE TO OFFICE ACTION RECEIVED
Thursday, February 20, 2020TEAS CHANGE OF CORRESPONDENCE RECEIVED
Thursday, February 20, 2020APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Thursday, February 20, 2020ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Thursday, February 20, 2020TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Thursday, February 20, 2020TEAS CHANGE OF OWNER ADDRESS RECEIVED
Saturday, December 28, 2019REFUSAL PROCESSED BY IB
Friday, December 6, 2019NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Thursday, December 5, 2019REFUSAL PROCESSED BY MPU
Wednesday, November 13, 2019NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Tuesday, November 12, 2019NON-FINAL ACTION WRITTEN
Tuesday, November 12, 2019APPLICATION FILING RECEIPT MAILED
Friday, November 8, 2019ASSIGNED TO EXAMINER
Friday, November 8, 2019NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Thursday, October 31, 2019SN ASSIGNED FOR SECT 66A APPL FROM IB